Repurposing Halicin as a potent covalent inhibitor for the SARS-CoV-2 main protease. Academic Article uri icon

abstract

  • The rapid spread of COVID-19 has caused a worldwide public health crisis. For prompt and effective development of antivirals for SARS-CoV-2, the pathogen of COVID-19, drug repurposing has been broadly conducted by targeting the main protease (MPro), a key enzyme responsible for the replication of virus inside the host. In this study, we evaluate the inhibition potency of a nitrothiazole-containing drug, halicin, and reveal its reaction and interaction mechanism with MPro. The in vitro potency test shows that halicin inhibits the activity of MPro an IC50 of 181.7nM. Native mass spectrometry and X-ray crystallography studies clearly indicate that the nitrothiazole fragment of halicin covalently binds to the catalytic cysteine C145 of MPro. Interaction and conformational changes inside the active site of MPro suggest a favorable nucleophilic aromatic substitution reaction mechanism between MPro C145 and halicin, explaining the high inhibition potency of halicin towards MPro.

published proceedings

  • Curr Res Chem Biol

altmetric score

  • 9.25

author list (cited authors)

  • Yang, K. S., Alex Kuo, S., Blankenship, L. R., Geng, Z. Z., Li, S. G., Russell, D. H., ... Liu, W. R.

citation count

  • 4

complete list of authors

  • Yang, Kai S||Alex Kuo, Syuan-Ting||Blankenship, Lauren R||Geng, Zhi Zachary||Li, Shuhua G||Russell, David H||Yan, Xin||Xu, Shiqing||Liu, Wenshe Ray

publication date

  • January 2022